Ignite Creation Date:
2025-12-24 @ 12:23 PM
Ignite Modification Date:
2026-01-30 @ 11:12 PM
Study NCT ID:
NCT03751761
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2018-11-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Sponsor:
Asan Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
AMC1803
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None